SRPK1 and cancer: SCO‐101 is a drug described as an inhibitor of ATP‐Binding Cassette (ABC) efflux pumps and of SRPK1 [166], which displayed anti‐cancer potential in combination with docetaxel in triple negative breast cancer cells [167].